115440-10-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-1,2-diamino-5-fluorobenzene is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-1,2-diamino-5-fluorobenzene is utilized as an intermediate in the production of agrochemicals, helping to create compounds that can enhance crop protection and yield.
Used in Dye and Pigment Manufacturing:
3-Bromo-1,2-diamino-5-fluorobenzene is employed as a building block in the manufacturing of dyes and pigments, contributing to the creation of a wide range of colorants for various applications.
Safety Considerations:
Given its potential hazardous nature, 3-Bromo-1,2-diamino-5-fluorobenzene should be handled and stored with care, adhering to proper safety protocols to ensure the safety of workers and the environment.

Upstream product

• 10472-88-5 4-fluoro-2-bromo-6-nitroaniline 
• 364-78-3 2-nitro-4-fluoroaniline 
• 1575-38-8 3,5-dibromo-1,2-phenylendiamine 

Downstream Products

• 1245642-98-1 4-bromo-6-fluoro-1H-benzo[d]imidazole 
• 937013-96-2 4-bromo-6-fluoro-1H-benzo[d][1,2,3]triazole 
• 1628908-19-9 5-bromo-7-fluoroquinoxaline 
• 1123738-30-6 C₁₉H₁₉FN₄ 
• 1239719-92-6 C₁₃H₇BrF₂N₂ 
• 1092500-70-3 8-bromo-6-fluoro-2-(3,4,5-trimethoxy-phenyl)-quinoxaline 

Relevant academic research and scientific papers

FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN

Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier and methods of treating pain in a subject in need thereof.

Fluorine atom substituted benzo heterocycle based conjugated molecule material as well as preparation method and application thereof

The invention discloses a fluorine atom substituted benzo heterocycle based conjugated molecule material as well as a preparation method and application thereof. The conjugated molecule material is ofan acceptor-donor-acceptor type structure, wherein an a

NOVEL COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

Provided are a compound for an organic light emitting device and an organic light emitting device comprising the same. To this end, it is possible to provide a compound for an organic light emitting device which can be used as a host, a hole-transport material, or an electron-transport material capable of enhancing light-emitting efficiency of phosphorescent light-emitting materials by having outstanding electrical stability, an electron and hole transportability, and a high level of triplet state energy, and the organic light emitting device.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

Structure-guided design of AMP mimics that inhibit fructose-1,6- bisphosphatase with high affinity and specificity

AMP binding sites are commonly used by nature for allosteric regulation of enzymes controlling the production and metabolism of carbohydrates and lipids. Since many of these enzymes represent potential drug targets for metabolic diseases, efforts were ini

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.